Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
240.71
+0.94 (0.39%)
At close: Nov 17, 2026, 4:00 PM EST
239.75
-0.96 (-0.40%)
After-hours: Nov 17, 2026, 6:56 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

Record Q3 revenue of $1.24B, up 10% YoY, supported higher FY26 guidance to $4.775B-$4.85B. Ziihera, MODEYSO and Actio expand growth opportunities alongside durable sleep and epilepsy franchises.

Phoebe Tan
Analyst, Jefferies

Perfect. My name is Phoebe Tan. I work with Akash Tewari, and he's currently at a lunch, and he'll be running over shortly. I have the pleasure of introducing Jazz Pharmaceuticals. I'll pass it over for intro remarks.

Renee Gala
President and CEO, Jazz Pharmaceuticals

Yeah, great. Thanks.

John Bluth
Head of Investor Relations, Jazz Pharmaceuticals

Thanks very much, Phoebe, for having us here. Renee and I will be making some forward-looking statements today, so please do refer to the risk factors in our securities filings. If we do refer to any guidance, it'll be the guidance as of our last earnings update, and that may include reference to non-GAAP financials, so please do look at the reconciliations that we provide there. Now I'd like to hand it over to our CEO, Renee Gala, who can tell you more about Jazz Pharmaceuticals.

Renee Gala
President and CEO, Jazz Pharmaceuticals

Great. Thank you, and thanks for all of you for joining. Hopefully, Akash will be here shortly. I am really excited to be here with all of you today. It's an incredible time to be at Jazz Pharmaceuticals right now as we continue building a more innovative and diversified company for the future. I would say that starts looking at our execution across the year. We've had excellent execution, which we announced as recent in our most recent third quarter earnings. We had record revenues of $1.24 billion, 10% year-over-year growth, giving us the confidence once again to raise our full-year guidance to $4.775 billion-$4.85 billion for 2026. As you look across commercial, our pipeline, and business development, we're seeing positive momentum across each of those.

Really driving our commercial performance and giving us the confidence to raise the guidance came across our sleep, epilepsy, and oncology portfolios, all performing well. In terms of our pipeline, we had our most recent approval for Ziihera in first-line metastatic GEA, HER2-positive metastatic GEA. This is a very important approval for us. The launch is off to a great start, and all of that momentum is backed by really strong clinical data behind the GEA study, which showed 27 months of median overall survival, which is unprecedented in this patient population. We are investing significantly behind this molecule with an extensive development program and giving us the confidence to provide peak sales guidance of $3 billion-$5 billion over the course of the life of this program, backed by the various development programs that we're expanding into.

Just to close from a value-driving perspective, we're investing behind commercial, investing behind our pipeline, but also investing in business development. We closed the Actio transaction in the third quarter of this year. We're excited to share data from that program later this quarter at a major medical conference that will be upcoming. We're excited to be able to demonstrate what we are bringing into the company to provide additional growth drivers, being very disciplined about our approach to business development and aligned to our rare disease strategy that we outlined earlier this year. Importantly, we're well capitalized with a strong balance sheet and continued strong cash flows to be able to invest in each of these drivers of our business and look forward to sharing more throughout the Q&A.

Phoebe Tan
Analyst, Jefferies

Perfect. Just building off of that, with Zani, MODEYSO , and Actio together, it seems like you're adding growth opportunities to franchises that you already have. How much of an advantage does the existing infrastructure provide for earnings and synergy?

Renee Gala
President and CEO, Jazz Pharmaceuticals

Yeah, so certainly, as we outlined earlier this year, we had every intention of sharpening our focus in rare disease, and in particular, when it comes to business development, building on our rare epilepsy, rare sleep, and rare oncology portfolios, and potentially, how are you? And potentially expanding beyond that into other areas of rare disease. Certainly, we can get more operating leverage out of our existing franchises when we're building greater breadth on the expertise and experience that we already have. The capabilities that we have, for example, for Actio, will bode quite nicely as we continue to rapidly push that program forward. So, we'll continue investing in business development and look at opportunities to grow the business in that way and then continue to invest in our existing organic business as well.

Akash Tewari
Analyst, Jefferies

Okay, there we go. Nice bridge. Give me a little time to catch my breath. I really do appreciate, Renee, you coming over, though. It's great to have you. I can tell you, personally, Jazz Pharmaceuticals is one of the most exciting names in our opinion going into next year. I think it's a big credit to really what you're delivering and building on. I want to start with that, because I feel like with investor discussions, when it goes to the pipeline, you have the post-Enhertu trial, there's the Zani launch, and that's pretty much it. When I look at the catalysts you have, particularly in the first half of the year, there's a lot of dark horses that are actually super accretive because you already have an existing sales force. I think about Actio and how quickly that can get on the market.

I think about a potential CRC Zani pan-tumor indication. I think about MODEYSO working in kind of frontline glioblastoma. I can't help but think all of those would be highly accretive to your current business. Talk to me about, f irst of all, do you think the street is accounting for that opportunity right now? Could you size up some of the revenue opportunities, if you can, with some of those, let's say, under-followed opportunities?

Renee Gala
President and CEO, Jazz Pharmaceuticals

Yeah. I'm not sure I am best positioned to say what investors are getting or not. I can say what we're focused on and what we're focused on delivering, myself as CEO, other members of the team I see in the audience. We are highly focused on building a durable, diversified business, and one that is not solely dependent on business development going forward. We have executed some incredible deals that we are all really proud of. In particular, in the last question, we talked about the ability to invest further in areas where you already have capabilities and expertise. With MODEYSO , which came to us through the Chimerix acquisition, that is an asset that we've said we think has $500 million peak potential in the U.S.

That asset is performing well, and financially, from a discipline perspective, that acquisition was less than $900 million. We have an incredible asset that came with it, great expertise in neuro-oncology, but also real cash benefits that come in the form of $200 million in deferred tax assets. We had a priority review voucher that came that we sold for $200 million, $100 million of that came back to Jazz Pharmaceuticals. When you just step back and look at the discipline and value that can be created through that transaction, those are the type of deals that I think bode very well for our business and for our shareholders. When it comes to Actio, this is another opportunity to have a meaningful impact for patients. There's nothing approved in KCNT1 epilepsy, and this is a very severe, debilitating form of epilepsy.

There's some anecdotes already available in the public about patients that have been treated through EAP, but we're excited to share data later this quarter, as I mentioned, which I think will give investors a really good view on the type of efficacy we can expect to see with this molecule. When we look broadly about the opportunity to bring these assets into our business while we are simultaneously expanding our R&D capabilities and now have Jazz-discovered assets that have come from Jazz Pharmaceuticals research lab into the clinic, that's created more durability into our business, where we can both build on the business development side, but also with greater capacity in R&D, continue to push forward our own R&D programs as well.

Akash Tewari
Analyst, Jefferies

Understood. Just to highlight a bit on that, because again, where I feel like people miss is, I mean, these couldn't just be, will matter at the end of the decade. These could start impacting the P&L maybe in 2027 and 2028. Let's start a bit with, we have, I think, ACTION, the frontline MODEYSO glioblastoma study reading out. My guess is you probably already have some frontline use given it's such a debilitating disorder. But can you remind us when does that study come out? What's your team's internal confidence that you'll see a positive signal given the data you've already generated? Then how quickly does that get you to Because you're well on the way to that $500 million run rate for MODEYSO already. How quickly does that result actually translate to the bottom line in terms of commercial performance?

Renee Gala
President and CEO, Jazz Pharmaceuticals

Yeah. So, I think you're right. We probably already have some first-line use, but the ACTION study serves as a confirmatory study and a frontline study for MODEYSO . Of course, we do not promote off-label. We only promote for the medicine's approved use, but we do expect that to read out in the first half of next year. We are still gaining insight into the duration of treatment with respect to MODEYSO , and so I think there are a couple of different angles in terms of continuing to see growth with that product. One is first-line approval and being able to have that in the label, which would have the use earlier. Two would be getting a better feel for duration of therapy. Then, I would say three, continued penetration into the, m edicine is well-known, but continued penetration both through institutions and into the community.

Neuro-oncology for us is an incredible area of interest, significant unmet need for these patients that are taking MODEYSO . They've had no innovation for-

Akash Tewari
Analyst, Jefferies

Right.

Renee Gala
President and CEO, Jazz Pharmaceuticals

60 years. This is the first approved therapy that they've had access to. This is an area we would love to also build around.

Akash Tewari
Analyst, Jefferies

Maybe a nice bridge to Actio. I can't help but think you have a sales force with Epidiolex. This, I don't even, I mean, you may have very limited additional sales reps. Maybe you don't need it at all. To your point, we've seen two case studies where we're seeing patients unfortunately have a baseline epilepsy, over 100, where they go almost symptom-free. That is, I mean, that's great for patients, but that's rare to find. Talk to us about the data we're going to get at AES. Sounds like we might get some additional symptom data. Then, can you comment a bit on KYRON, which is the confirmatory study, and when that could actually end up reading out?

Then ultimately, I mean, if there was ever a candidate for kind of a CNPV, I know it doesn't exist anymore, but how quickly could a product like this actually get onto the market? What has been your discussions with the agency about really making sure this gets to patients as soon as possible?

Renee Gala
President and CEO, Jazz Pharmaceuticals

Yeah. So, maybe I'll take the first and last of those questions, and then maybe John, you can comment a bit on KYRON. So, the data you should expect to see later this quarter will be a subset of patients, and I would focus on the seizure control data that comes from that. As you said, there's been some really stunning data that we've seen thus far, open-label type of data in an EAP environment, but really meaningful when you're thinking about infants suffering from KCNT1 epilepsy, because the development often just stops, and so these seizures are robbing them of life. So this is why many of us come into this industry when you have the opportunity to see such meaningful impact. With respect to the dialogues with the agency, we'll provide more guidance there as that progresses, but those dialogues are going quite well.

The interactions are quite positive. I would just say, stepping back, I have been thrilled to see the FDA really leaning more and more into rare disease and understanding that you need better fit-for-purpose guidelines, and guidelines that can be durable and predictable as you are running studies in much smaller patient populations. Do you want to comment a bit on KYRON?

John Bluth
Head of Investor Relations, Jazz Pharmaceuticals

Sure. KYRON is the ongoing trial that we believe could be registrational with ABS-1230. It is taking a look at patients who have disease over a 12-week period. There is an arm that is placebo-controlled, and we do expect to present some data from this ongoing trial at the conference in early December. Depending on the quality of that data and the dialogue we have with the FDA, we hope we can move the program as quickly as we can to patients.

Akash Tewari
Analyst, Jefferies

Understood. Now, going a bit into guidance, and I think Phil does a great job. Also, help us understand with the Zani launch, because to me, you guys have given your long-term views on Zani, $3 billion-$5 billion. That kind of speaks for itself. There is obviously an implied blockbuster number there for GEA. I think we will get, on our side, fixated on the launch uptake. You guys have said it is going to be rapid, but it is not a bolus, and there are 3,000-4,000 patients out there, and then you divide that from a quarter perspective. So, help us understand the cadence and expectations going into next year. What is your long-term view about whether this will be standard of care changing versus what we have seen with the Merck regimen?

Number two, when we think about uptake going into 2027, what is the right expectation, and how is Phil going to approach guiding to that? Is that something he might call out specifically for 2027?

Renee Gala
President and CEO, Jazz Pharmaceuticals

Yeah. I won't speak on Phil's behalf today, but typically we don't give product-specific guidance. When we get to our year-end earnings in February, we'll provide revenue guidance for the year and determine what, if any, we give specific to individual products or franchises. Stepping back and looking at where we are with Ziihera and GEA, as I'd mentioned earlier, the data that we've seen here in OS of 27 months with the triplet is unprecedented in this patient population. The early signs that we are seeing, monitoring, and the launch have all been very positive. We have more than three-quarters of physicians in our survey that communicate the intent to prescribe, and that's very strong at this stage. High unaided awareness.

If you just look at that approval at the end of August, so we had one month, which would have been the month of September, in the third quarter. What we saw there was a 40% increase in daily vials, daily average vials for September. We saw a threefold increase in new accounts ordering, 80% of which was in the community. That's where we need to continue to focus because about 70% of these patients are in the community. All of our early launch metrics are quite positive. Again, it is early. As you mentioned, there's not a bolus of patients that are going to come from EAP or otherwise. We would expect patients to be prescribed as they present over the course of the year. There are 3,000 -4 ,000 addressable patients that we think will be good candidates for this.

I would say in terms of standard of care, that when you look at this data, I do expect it to be the standard of care. I do expect it to be practice-changing. That is additional work that you have to do in the community to change behaviors, and when you have data like this, it is much easier to do that because this is about extending life. It's about extending overall survival. I would say the other thing to keep in mind with GEA, we have a label that is for HER2-positive first-line GEA regardless of PD-L1 status, and that is unique, and it's something that I think also simplifies the prescribing decisions and behaviors.

Akash Tewari
Analyst, Jefferies

Understood. Now, thinking a bit about, and I know there might be limited things you can say, but you do have breakthrough designation on colorectal cancer based on emerging data with Zani. If we look at Enhertu, the pan-tumor indication was a significant growth driver for them. It was something commercially important, and that's something you guys have really gone for early, an agnostic type of label. Talk to me about what discussions you could be having with the agency, because I think your pan-tumor study ends very shortly, about an accelerated approval pathway in CRC, and when could you maybe update the street on really filing timelines there?

Renee Gala
President and CEO, Jazz Pharmaceuticals

Yeah. Discussions are ongoing. We are highly encouraged by the data that we are seeing. This is a significant unmet need, and I would say stay tuned there. You are right, I am not going to have a lot of definitive guidance to give there, but I am highly encouraged by the opportunity and the potential impact for patients.

Akash Tewari
Analyst, Jefferies

Understood. Now, it is interesting, I remember talking to Bruce, and he always felt like, "Look, guys, this sodium oxybate business is going to be more durable than you think." But there is this dynamic of, if public market investors don't give you the credit for it, then it becomes kind of you have to disprove a negative. I think to his credit, no one would have modeled sodium oxybate growing 15% in a year where generics entered. I mean, I know I didn't. I know the Street didn't. Then we have orexins launching, which is an MOA even your team is quite interested in, and I think a lot of investors are as well. But there is a perception of, well, now there is going to be a big cut in terms of where sodium oxybate is used, switch, and really the commercial opportunity.

That has been another area where I think your team has been fairly consistent that you don't see orexins necessarily removing the market opportunity for sodium oxybate. But talk to me about your confidence on the durability of sodium oxybate going out to the end of the decade, and how does the market really change as orexins get onto the market for NT1?

Renee Gala
President and CEO, Jazz Pharmaceuticals

Yeah. This business, this oxybate business, and I would say the low-sodium Xywav business, has been incredibly durable, and that comes directly to the differentiation of the product, low sodium, flexible dosing, and we have shown through the data we continue to generate that that is of immense importance to this patient population because narcolepsy patients, idiopathic hypersomnia patients are predisposed to cardiovascular conditions. So high-sodium oxybate has a very, very heavy sodium load, and so if you have a modifiable risk factor that you can address with low-sodium Xywav, it is meaningful.

I think when you look at our continued robust business there, both in narcolepsy and idiopathic hypersomnia, we had 12% year-over-year growth. In the third quarter, added 425 patients. Of those 425 patient adds, 325 of those came from idiopathic hypersomnia, 100 came from narcolepsy. These are net patient adds. I mention that because we are the only drug approved for idiopathic hypersomnia. That is the larger part of our growth driver. The orexin that was just approved, the pricing was largely as we had expected. It is approved in NT1 narcolepsy. Again, we added the majority of patients that were idiopathic hypersomnia patients, about 100 narcolepsy patients. The impact to our business that I would expect we may see is potentially a delay in new patient starts that are NT1 patients, because typically you would cycle through wake-promoting agents before getting to oxybate therapy.

Oxybate is not first-line therapy. Having another wake-promoting agent, hopefully a better wake-promoting agent, is great for patients, and I would expect that to not be hugely impactful to our business. I would expect ultimately orexins will be complementary to oxybates, just given orexins are not targeting disrupted nighttime sleep.

Akash Tewari
Analyst, Jefferies

Right.

Renee Gala
President and CEO, Jazz Pharmaceuticals

That's incredibly important. Then I would just remind you as you step back and look at our overall business with Xywav and our overall patient population, we have 17,550 patients at the end of Q3. About 1/3 of those were idiopathic hypersomnia. The other 2/3 were narcolepsy, and NT1 in general is a smaller portion of narcolepsy patients.

40%-60% is generally the number cited when it comes to epidemiology in terms of 40% NT1.

Akash Tewari
Analyst, Jefferies

Really just-

Renee Gala
President and CEO, Jazz Pharmaceuticals

60% NT2.

Akash Tewari
Analyst, Jefferies

Almost the way you are saying it, 50 patients basically, because if you are thinking about 100 narcolepsy, but then even there you are cutting NT1, NT2, it sounds like the delay would be on the 50 patient adds in NT1 is what we are saying versus the, what, 250+ on IH. Is that fair?

Renee Gala
President and CEO, Jazz Pharmaceuticals

Yeah. I mean, we had 325 in IH, but yes, what I am referring to is a percentage of our-

Akash Tewari
Analyst, Jefferies

Okay.

Renee Gala
President and CEO, Jazz Pharmaceuticals

New narcolepsy patient starts, specific NT1 starts. We also have not seen much impact, if at all, from authorized generics or multi-source generics to our Xywav business, and I think that goes back to the strong differentiation of Xywav being the only low-sodium oxybate, the patient support services that we provide, which generics do not, and the fact that we compete and have been competing for years with high-sodium oxybates with our low-sodium Xywav, which has performed really well.

Akash Tewari
Analyst, Jefferies

Point well taken. It's interesting. Renee, the stock has more than doubled under your tenure, and yet you could argue it's trading at still a very low multiple. I would argue that, maybe even seven times or lower. Depends on what you have. But there is this kind of dynamic of you solved the patent cliff, right? sodium oxybate's $2 billion, you have Epidiolex, you have a billion-dollar oncology business, you're overlaying Zani and MODEYSO . We're kind of past that point in terms of long-term peak sales. Maybe where I think there's the anxiety is just understanding the cadence in the near term, right? And that's where maybe the desire for mid or longer-term guidance might be a way to kind of unlock that potential. Is there an appetite for your team to give investors OpEx or margin or revenue guidance three to five years out?

Or this is really not something that you find productive, you'll show it with the performance, and that'll really do the job?

Renee Gala
President and CEO, Jazz Pharmaceuticals

I think you've rightly stated, we have three separate billion-dollar-plus franchises now. That's a very different business than what Jazz looked like even several years ago. We have an almost $2 billion sleep franchise, more than a billion-dollar epilepsy franchise that we have line of sight to significant durability. We don't expect generics to come into that business before the very late 2030s, so that's a franchise we can continue to build around. Oncology, we have Ziihera now as an important future growth driver with $3 billion-$5 billion of peak potential, as we've communicated. So, to me, stepping back, that communicates where we do expect meaningful growth to come from. We're also well-capitalized to be able to invest in that commercial business. Our pipeline has a number of important inflection points. We talked about the ACTION study with MODEYSO .

We will be continuing to push forward ABS-1230, the Actio compound. We also have metastatic breast cancer reading out at the end of 2027, early 2028 for Ziihera. There are a number of value inflection points, and we have a strong balance sheet. We are well-capitalized to keep investing there, and we can augment that with smart, disciplined business development that can allow us to get more operating leverage out of those franchises and allow us to also then put more into R&D, where we think we can create more long-term value for patients and also for shareholders.

Akash Tewari
Analyst, Jefferies

I take that as show, don't tell in terms of appetite for long-term guidance.

Renee Gala
President and CEO, Jazz Pharmaceuticals

Execution says a lot. When you do and deliver on what you say you are going to do, I think that has had a really important impact with the movement of the stock over the last 15, 18 months.

Akash Tewari
Analyst, Jefferies

Yeah. Understood. I really do appreciate it. Thanks, everyone, for joining us, and thank you, Renee.

Renee Gala
President and CEO, Jazz Pharmaceuticals

Great. Thank you.